نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - lisuride maleate 0.2mg - tablet - 0.2 mg - active: lisuride maleate 0.2mg excipient: lactose monohydrate magnesium stearate powdered cellulose sodium calcium edetate, hydrate tartaric acid - as a dopamine agonist in: parkinson's disease, postencephalitic parkinsonism, parkinsonism of other origin (with the exception of the medicine-induced form)

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - carbidopa anhydrous 25 mg - carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from the addition of carbidopa. since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin b6), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. this was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. in deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. it should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. carbidopa is contraindicated in patients with known hypersensitivity to any component of this drug. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with levodopa. carbidopa-levodopa, or levodopa may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions ). levodopa or carbidopa-levodopa products, with or without carbidopa, are contraindicated in patients with narrow-angle glaucoma.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. carbidopa and levodopa orally disintegrating tablets are indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa therapy. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa,

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

physicians total care, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa - unii:mnx7r8c5vo), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa 10 mg - carbidopa and levodopa tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. this product is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa therapy. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is benefic

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

schwarz pharma - carbidopa (unii: mnx7r8c5vo) (carbidopa - unii:mnx7r8c5vo), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - tablet, orally disintegrating - 25 mg - parcopa®   is indicated in the treatment of the symptoms of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. parcopa®   is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. however, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. although the administration of carbidopa permits control of parkinsonism and parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing naus

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa 25 mg - carbidopa and levodopa tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. this product is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial othe

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. this product is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial othe

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of the symptoms of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. carbidopa and levodopa orally disintegrating tablets are indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa and levodopa therapy. although the administration of carbidopa permits control of parkinsonism and parkinson’s disease with much lower doses of levodopa,

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

organon singapore pte. ltd. - carbidopa; levodopa - tablet - 50 mg - carbidopa 50 mg; levodopa 200 mg

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; sucrose; magnesium stearate; croscarmellose sodium; glycerol; povidone; iron oxide red; maize starch; hypromellose; polysorbate 80 - l.c.e. sandoz 200/50/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.